2026-07-21 カリフォルニア大学サンディエゴ校（UCSD）
＜関連情報＞
- https://today.ucsd.edu/story/personalized-gene-therapy-helps-teen-with-rare-form-of-severe-epilepsy-walk-independently
- https://www.nature.com/articles/s41591-026-04527-y
SCN2A関連発達性てんかん性脳症に対する個別化アンチセンスオリゴヌクレオチド Individualized antisense oligonucleotides for SCN2A-related developmental epileptic encephalopathy
Olivia Kim-McManus,Laurence Mignon,Julie Douville,He Pu,Catherine Parisien,Sarah Glass,C. Frank Bennett,Janelle Celso,Kendall Robbins,Hoameng Ung,Heather Olson,Stephen F. Kingsmore,Steven Petrou,Stanley T. Crooke,Joseph G. Gleeson & Elizabeth Berry-Kravis
Nature Medicine Published:21 July 2026
DOI:https://doi.org/10.1038/s41591-026-04527-y
Abstract
SCN2A variants are among the most common genetic causes of developmental and epileptic encephalopathies (DEEs), which can present with uncontrolled seizures at birth and account for 1–2% of all epileptic encephalopathies. A substantial fraction of causal variants are gain-of-function or mixed-function variants associated with increased channel open probability or greater sodium current flux. Here two parallel n = 1 clinical studies were conducted in two patients (9-year-old and 14-year-old boys) with SCN2A-related DEE. Individualized allele-selective antisense oligonucleotides (ASOs) were designed to target heterozygous intronic single-nucleotide polymorphisms (SNPs) for decreased expression of mutant SCN2A transcript while preserving the wild-type copy. Primary endpoints included quantitative change from baseline in seizure frequency and neurodevelopment, including motor scores. Efficacy measures were also individualized to each patient’s phenotype, including refractory seizures, developmental delay, autism spectrum disorder, choreoathetosis and gastrointestinal dysfunction. Patients experienced a reduction in seizure frequency (26% and 90% in the two patients, respectively), decreased use of concomitant medications and improvement in neurodevelopmental skills. Both ASOs were well tolerated, with no ASO-related serious adverse events. Continued long-term follow-up of these preliminary positive safety and efficacy findings is needed to confirm the disease-modifying potential of these ASOs. Haplotype phasing in a separate cohort of infants with SCN2A-related disorder (SCN2A-RD), diagnosed by rapid whole-genome sequencing, identified 16% of patients with compatible SNPs. These data provide a pathway from n = 1 to n of more patients with SCN2A-RD and other monogenic disorders. ClinicalTrials.gov registration: NCT06314490.
